

EXCEPTIONAL GROWTH,  
 EXCEPTIONAL YEAR

 FOURTH-QUARTER 2020  
 SALES WORLDWIDE

**\$10.7**  
 billion

**+28.4%**<sup>1</sup>  
 on organic basis\*

 SALES PERFORMANCE  
 ACROSS ABBOTT


**\$4.3B**

DIAGNOSTICS

**\$3.3B**

MEDICAL DEVICES

**\$1.9B**

NUTRITION

**\$1.1B**

 ESTABLISHED  
 PHARMACEUTICALS

 FULL-YEAR 2020  
 SALES WORLDWIDE

**\$34.6**  
 billion

**+9.8%**<sup>2</sup>  
 on organic basis\*

## FULL-YEAR 2021 GUIDANCE

 ADJUSTED DILUTED EPS<sup>3</sup>

AT LEAST

**\$5.00**

 REFLECTING GROWTH  
 OF MORE THAN

**35%** VERSUS  
 PRIOR YEAR

## PIPELINE ADVANCES

ACROSS OUR DIVERSE BUSINESSES IN 2020

## DIAGNOSTICS

**FIRST RAPID HANDHELD BLOOD  
 TEST FOR CONCUSSIONS**

- ▶ FDA clearance for 15-minute blood test to help evaluate mild traumatic brain injury, commonly known as concussion

 CARDIOVASCULAR  
 DEVICES

**MARKET EXPANSION WITH  
 KEY APPROVALS**

- ▶ Expanded Medicare (CMS) reimbursement for MitraClip®, significantly increasing insurance coverage
- ▶ FDA approval for HeartMate 3™ heart pump for pediatric patients battling advanced heart failure

## NUTRITION

**NEW PEDIALYTE PRODUCTS**

- ▶ Expanded Pedialyte® product portfolio with four new products: Pedialyte with Immune Support, Pedialyte Sport, Pedialyte Organic and Pedialyte Electrolyte Water with Zero Sugar

**INNOVATION FOR ACCESS**

- ▶ New product launches: FDA clearance for FreeStyle® Libre 2<sup>†</sup> for adults and kids 4+, CE Mark for FreeStyle Libre 3, CE Mark for FreeStyle Libre 3 and Libre Sense Glucose Sport Biosensor
- ▶ Announced long-term support for American Diabetes Association health equity initiative to advance access to care and technology for underserved diabetes communities

## NEUROMODULATION

**REMOTELY CONNECTING  
 DOCTORS AND PATIENTS**

- ▶ NeuroSphere™ myPath™ digital health app will allow chronic pain patients to track, analyze and report pain relief and general well-being associated with therapy during neurostimulation trial period
- ▶ App connects patients to physicians with real-time data access

\*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 27, 2021, available at [www.abbottinvestor.com](http://www.abbottinvestor.com).

1. On a GAAP basis, fourth-quarter Abbott sales increased 28.7%. 2. On a GAAP basis, full-year Abbott sales increased 8.5%. 3. Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least \$3.74, reflecting growth of at least 50% versus the prior year. Abbott forecasts specified items for the full-year 2021 of \$1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses.

† Find important safety information about the FreeStyle Libre portfolio: [www.freestylelibre.us/safety-information](http://www.freestylelibre.us/safety-information).

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2019 and in Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.